Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2venetoclax 1tagraxofusp 1merphos 1lorvotuzumab mertansine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Thiotepa 1Tacrolimus 1Salvia hispanica seed extract 1Ranitidine 1Methotrexate 1MK 2206 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Blastic Plasmacytoid Dendritic Cell Neoplasm × tagraxofusp × Clear all
NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Stemline Therapeutics, Inc.

Phase 1/2 Completed
138 enrolled 23 charts 2 FDA
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡